U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07469800) titled 'Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity' on Feb. 27.
Brief Summary: A multicenter, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of IBI362 in participants with mild to moderate hypertension complicated by overweight/obesity who have not received antihypertensive drug treatment
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Overweight
Obesity
Hypertensive
Intervention:
DRUG: IBI362
IBI362 will be administered subcutaneously once weekly (QW) in a step-up dose titration regimen over 48 weeks:
* Weeks 1-4: 2 mg QW
* Weeks...